

Lisa H Butterfield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4042750/publications.pdf>

Version: 2024-02-01

188
papers

12,963
citations

31949

53
h-index

30894

102
g-index

199
all docs

199
docs citations

199
times ranked

17165
citing authors

#	ARTICLE	IF	CITATIONS
1	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
2	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	5.1	921
3	Induction of CD8 ⁺ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With I \pm -Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 330-336.	0.8	519
4	Immunotherapy of cancer in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 309-335.	157.7	379
5	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1744.	3.8	312
6	Baseline circulating IL-17 predicts toxicity while TGF- β 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
7	Current Developments in Cancer Vaccines and Cellular Immunotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2415-2432.	0.8	287
8	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 480-492.	1.6	284
9	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. <i>PLoS ONE</i> , 2014, 9, e87705.	1.1	261
10	Dendritic Cell-Based Cancer Vaccines. <i>Journal of Immunology</i> , 2018, 200, 443-449.	0.4	238
11	A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four I \pm -Fetoprotein Peptides. <i>Clinical Cancer Research</i> , 2006, 12, 2817-2825.	3.2	217
12	Next Generation of Immunotherapy for Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3445-3455.	0.8	215
13	Cancer vaccines. <i>BMJ</i> , The, 2015, 350, h988-h988.	3.0	199
14	Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. <i>Clinical Cancer Research</i> , 2003, 9, 998-1008.	3.2	197
15	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
16	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
17	Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas. <i>Journal of Clinical Oncology</i> , 2014, 32, 2050-2058.	0.8	167
18	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. , 2016, 4, 76.		155

#	ARTICLE	IF	CITATIONS
19	Immunotherapy of hepatocellular carcinoma. <i>Oncolimmunology</i> , 2012, 1, 48-55.	2.1	146
20	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
21	Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/â” Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-Î±2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. <i>Clinical Cancer Research</i> , 2009, 15, 1443-1451.	3.2	136
22	T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human Î± Fetoprotein. <i>Journal of Immunology</i> , 2001, 166, 5300-5308.	0.4	131
23	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. <i>Immunity</i> , 2012, 37, 1-2.	6.6	131
24	From Cytoprotection to Tumor Suppression: The Multifactorial Role of Peroxiredoxins. <i>Antioxidants and Redox Signaling</i> , 1999, 1, 385-402.	2.5	129
25	Zinc in innate and adaptive tumor immunity. <i>Journal of Translational Medicine</i> , 2010, 8, 118.	1.8	129
26	T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5902-8.	3.2	129
27	Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication. <i>Human Gene Therapy</i> , 2000, 11, 53-65.	1.4	124
28	Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?. <i>Frontiers in Immunology</i> , 2013, 4, 454.	2.2	120
29	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. <i>Oncolimmunology</i> , 2015, 4, e998538.	2.1	119
30	Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2433-2444.	3.2	118
31	Phase 1 clinical trial of adoptive immunotherapy using â€œoff-the-shelfâ€ activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. <i>Cytotherapy</i> , 2017, 19, 1225-1232.	0.3	117
32	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. <i>Journal of Translational Medicine</i> , 2007, 5, 67.	1.8	112
33	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. <i>Nature Medicine</i> , 2022, 28, 1167-1177.	15.2	112
34	Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. <i>Immunogenetics</i> , 1994, 40, 129-34.	1.2	110
35	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011, 17, 3064-3076.	3.2	108
36	Determinant spreading and tumor responses after peptide-based cancer immunotherapy. <i>Trends in Immunology</i> , 2003, 24, 58-61.	2.9	107

#	ARTICLE	IF	CITATIONS
37	Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 2462-2469.	0.4	107
38	Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy. <i>Journal of Immunotherapy</i> , 2004, 27, 354-367.	1.2	107
39	Adenovirus MART-1-engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 294-309.	1.2	104
40	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). <i>Journal of Clinical Oncology</i> , 2015, 33, 4066-4076.	0.8	101
41	A Randomized Phase II Trial of Multipitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). <i>Clinical Cancer Research</i> , 2013, 19, 4228-4238.	3.2	98
42	Immunotherapeutic strategies for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S232-S241.	0.6	93
43	Induction of Robust Type-1 CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. <i>Clinical Cancer Research</i> , 2015, 21, 286-294.	3.2	92
44	Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. <i>Cancer</i> , 2016, 122, 1270-1282.	2.0	91
45	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II clinical validation and regulatory considerations. , 2016, 4, 77.		87
46	In Vivo Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2. <i>Human Gene Therapy</i> , 1997, 8, 2173-2182.	1.4	86
47	Antioxidant Function of Recombinant Human Natural Killer Enhancing Factor. <i>Biochemical and Biophysical Research Communications</i> , 1995, 208, 964-969.	1.0	80
48	Tumor-Derived α -Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells. <i>Journal of Immunology</i> , 2014, 193, 5723-5732.	0.4	73
49	Cancer Immunotherapy Using Gene-Modified Dendritic Cells. <i>Current Gene Therapy</i> , 2002, 2, 57-78.	0.9	70
50	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 6325-6337.	3.9	70
51	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1157-1168.	0.6	69
52	Hierarchy of α -Fetoprotein (AFP)-Specific T Cell Responses in Subjects with AFP-Positive Hepatocellular Cancer. <i>Journal of Immunology</i> , 2006, 177, 712-721.	0.4	67
53	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
54	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. <i>Blood</i> , 2010, 116, 575-583.	0.6	63

#	ARTICLE	IF	CITATIONS
55	Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon- γ or TLR-9 Agonist and GM-CSF With Peptide Vaccination. <i>Journal of Immunotherapy</i> , 2012, 35, 702-710.	1.2	63
56	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
57	Generation of T-Cell Immunity to a Murine Melanoma Using MART-1-Engineered Dendritic Cells. <i>Journal of Immunotherapy</i> , 2000, 23, 59-66.	1.2	63
58	Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1931-1943.	2.0	62
59	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , 2018, 11, 429-438.	0.7	59
60	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
61	Human Dendritic Cell Maturation by Adenovirus Transduction Enhances Tumor Antigen-Specific T-Cell Responses. <i>Journal of Immunotherapy</i> , 2004, 27, 191-200.	1.2	57
62	Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human β -fetoprotein. <i>Molecular Immunology</i> , 2000, 37, 943-950.	1.0	51
63	AFP-specific CD4+ Helper T-cell Responses in Healthy Donors and HCC Patients. <i>Journal of Immunotherapy</i> , 2007, 30, 425-437.	1.2	50
64	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016, 130, 517-527.	1.4	49
65	Cancer-Related Symptom Clusters, Eosinophils, and Survival in Hepatobiliary Cancer: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2010, 39, 859-871.	0.6	47
66	Development of a Potency Assay for Human Dendritic Cells: IL-12p70 Production. <i>Journal of Immunotherapy</i> , 2008, 31, 89-100.	1.2	46
67	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". <i>Journal of Translational Medicine</i> , 2008, 6, 81.	1.8	45
68	Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. <i>Journal of Translational Medicine</i> , 2014, 12, 86.	1.8	45
69	A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. <i>European Urology</i> , 2015, 68, 365-371.	0.9	43
70	Multiplex serum biomarker assessments: technical and biostatistical issues. <i>Journal of Translational Medicine</i> , 2011, 9, 173.	1.8	41
71	Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens. <i>Molecular Therapy</i> , 2011, 19, 805-814.	3.7	41
72	Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-11.	3.3	41

#	ARTICLE	IF	CITATIONS
73	CD56dim CD16 ^{hi} Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- γ . <i>Frontiers in Immunology</i> , 2019, 10, 14.	2.2	41
74	Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 15.	2.2	39
75	Melanoma-associated leukoderma "immunology in black and white?". <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 796-804.	1.5	38
76	Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. <i>Cancer Gene Therapy</i> , 1999, 6, 523-536.	2.2	37
77	Melanoma cancer vaccines and anti-tumor T cell responses. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 301-310.	1.2	37
78	Function but not phenotype of melanoma peptide-specific CD8 ⁺ T cells correlate with survival in a multipeptide peptide vaccine trial (ECOG 1696). <i>International Journal of Cancer</i> , 2012, 131, 874-884.	2.3	37
79	Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1448-1458.	3.6	37
80	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018, 16, 184.	1.8	36
81	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
82	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
83	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	3.2	34
84	High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. <i>Cellular Immunology</i> , 2018, 323, 9-18.	1.4	34
85	Tumor-Derived α -Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells. <i>Cancer Immunology Research</i> , 2019, 7, 1001-1012.	1.6	31
86	Multiple antigen-engineered DC vaccines with or without IFN γ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
87	Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. <i>Journal of Translational Medicine</i> , 2007, 5, 68.	1.8	30
88	Ectopic T-bet Expression Licenses Dendritic Cells for IL-12-Independent Priming of Type 1 T Cells In Vitro. <i>Journal of Immunology</i> , 2009, 183, 7250-7258.	0.4	30
89	Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 121-133.	2.0	30
90	Recent advances in immunotherapy for hepatocellular cancer. <i>Swiss Medical Weekly</i> , 2007, 137, 83-90.	0.8	30

#	ARTICLE	IF	CITATIONS
91	Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. <i>Oncolmmunology</i> , 2012, 1, 448-457.	2.1	29
92	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. <i>Immunologic Research</i> , 2011, 50, 235-247.	1.3	28
93	Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer. <i>Psychosomatic Medicine</i> , 2018, 80, 483-491.	1.3	28
94	Genetic Immunotherapy for Cancer. <i>Oncologist</i> , 2000, 5, 87-98.	1.9	26
95	Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. <i>Cancer Research</i> , 2003, 63, 5607-14.	0.4	26
96	Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. <i>Cancer Gene Therapy</i> , 2005, 12, 516-527.	2.2	25
97	SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. <i>Journal of Translational Medicine</i> , 2011, 9, 155.	1.8	25
98	Molecular mimicry of MAGE-A6 and <i>Mycoplasma penetrans</i> HF-2 epitopes in the induction of antitumor CD8 ⁺ T-cell responses. <i>Oncolmmunology</i> , 2014, 3, e954501.	2.1	25
99	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 223.	1.8	25
100	Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned. <i>Clinical Trials</i> , 2011, 8, 298-310.	0.7	24
101	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. <i>Oncolmmunology</i> , 2012, 1, 287-357.	2.1	24
102	Lessons learned from cancer vaccine trials and target antigen choice. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 805-812.	2.0	24
103	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
104	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and SÅ©zary syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 423-434.	2.0	23
105	First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. <i>Journal of Translational Medicine</i> , 2019, 17, 271.	1.8	23
106	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. , 2016, 4, 38.		22
107	Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. <i>Gene</i> , 1997, 191, 129-134.	1.0	21
108	Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells. <i>Journal of Immunology</i> , 2004, 172, 4762-4769.	0.4	21

#	ARTICLE	IF	CITATIONS
109	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
110	Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Research, 2018, 28, 211-221.	0.6	21
111	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight, 2018, 3, .	2.3	21
112	Tumor-Derived Î±-Fetoprotein Directly Drives Human Natural Killerâ€™Cell Activation and Subsequent Cell Death. Cancer Immunology Research, 2017, 5, 493-502.	1.6	20
113	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
114	Impact of checkpoint blockade on cancer vaccineâ€™activated CD8+ T cell responses. Journal of Experimental Medicine, 2020, 217, .	4.2	20
115	Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology, 2004, 113, 472-481.	2.0	19
116	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. , 2016, 4, 24.		19
117	Melanoma vaccines: clinical status and immune endpoints. Melanoma Research, 2019, 29, 109-118.	0.6	19
118	Immunotherapy of hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2002, 2, 123-133.	1.4	18
119	Î±-Fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opinion on Biological Therapy, 2008, 8, 325-336.	1.4	18
120	Pitfalls in retrospective analyses of biomarkers: A case study with metastatic melanoma patients. Journal of Immunological Methods, 2012, 376, 108-112.	0.6	18
121	Neoadjuvant Pembrolizumab and High-Dose IFNÎ±-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	3.2	18
122	Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. , 2015, 3, 32.		17
123	Dendritic Cell Control of Immune Responses. Frontiers in Immunology, 2015, 6, 42.	2.2	17
124	Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen geneâ€™modified dendritic cell vaccines. Cancer Gene Therapy, 2002, 9, 875-883.	2.2	16
125	Activation of antigen-presenting cells by DNA delivery vectors. Expert Opinion on Biological Therapy, 2005, 5, 1019-1028.	1.4	16
126	NCI 8628: A randomized phase 2 study of zivâ€™Aflibercept and highâ€™dose interleukin 2 or highâ€™dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer, 2018, 124, 4332-4341.	2.0	15

#	ARTICLE	IF	CITATIONS
127	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1554-1567.	1.6	15
128	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
129	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
130	Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. <i>International Journal of Oncology</i> , 2011, 39, 245-53.	1.4	14
131	Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. , 2020, 8, e001619.		14
132	Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. <i>Cellular Immunology</i> , 2019, 335, 59-67.	1.4	13
133	Adverse childhood experiences (ACEs), cell-mediated immunity, and survival in the context of cancer. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 566-572.	2.0	13
134	Immunomodulatory impact of α -fetoprotein. <i>Trends in Immunology</i> , 2022, 43, 438-448.	2.9	13
135	The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. <i>Seminars in Cancer Biology</i> , 2018, 52, 12-15.	4.3	12
136	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT (Overlock		12
137	New approaches to the development of adenoviral dendritic cell vaccines in melanoma. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1399-408.	2.3	12
138	A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 783-788.	2.0	11
139	Interleukin 32 expression in human melanoma. <i>Journal of Translational Medicine</i> , 2019, 17, 113.	1.8	11
140	Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 7, 112-122.	1.8	10
141	Immunologic Monitoring of Cancer Vaccine Trials Using the ELISPOT Assay. <i>Methods in Molecular Biology</i> , 2014, 1102, 71-82.	0.4	9
142	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- γ but Not Observation in Intermediate Risk Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0132745.	1.1	9
143	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. <i>Journal of Translational Medicine</i> , 2017, 15, 39.	1.8	9
144	Rational design of peptide-based tumor vaccines. <i>Pharmaceutical Research</i> , 2002, 19, 926-932.	1.7	8

#	ARTICLE	IF	CITATIONS
145	Ependymomas: development of immunotherapeutic strategies. Expert Review of Neurotherapeutics, 2013, 13, 1089-1098.	1.4	8
146	Peptide Vaccine Therapy for Childhood Gliomas. Neurosurgery, 2013, 60, 113-119.	0.6	8
147	Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy, 2020, 22, 239-246.	0.3	7
148	The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine, 2022, 20, .	1.8	7
149	Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. , 2022, 10, e004310.		6
150	Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Contemporary Clinical Trials, 2004, 25, 400-407.	2.0	5
151	Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma. , 2013, 1, 19.		5
152	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
153	Dose-response evaluation of broccoli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).. Journal of Clinical Oncology, 2016, 34, e21022-e21022.	0.8	5
154	Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. Journal of Translational Medicine, 2022, 20, .	1.8	5
155	Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology, 2018, 155, 1684-1686.	0.6	4
156	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. , 2019, 7, 221.		4
157	Preamble to the 2015 SITC immunotherapy biomarkers taskforce. , 2015, 3, 8.		3
158	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th,) Tj ETQq0 0 0 rgBT /Over	1.8	3
159	Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and biomarker analysis.. Journal of Clinical Oncology, 2012, 30, 76-76.	0.8	3
160	Web-based stepped collaborative care intervention in the context of advanced cancer.. Journal of Clinical Oncology, 2014, 32, 9522-9522.	0.8	3
161	Measurements of Natural Killer (NK) Cells. Critical Reviews in Oncogenesis, 2014, 19, 47-55.	0.2	3
162	185"Peptide Vaccine Therapy for Childhood Gliomas. Neurosurgery, 2012, 71, E572.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Abstract LB-135: A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. , 2012, , .		2
164	Isolation, culture and propagation of natural killer cells. , 2010, , 125-135.		1
165	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. , 2015, 3, .		1
166	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
167	DNA and Dendritic Cell-Based Genetic Immunization Against Cancer. , 2002, , 179-198.		1
168	Cancer and the Immune System. , 0, , 573-591.		1
169	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. Blood, 2016, 128, 1649-1649.	0.6	1
170	Novel dendritic cell vaccine strategies. , 2022, , 109-135.		1
171	T Cell Responses to Alpha Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Cancer. Journal of Immunotherapy, 2004, 27, S20.	1.2	0
172	Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. , 2014, 2, .		0
173	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. Neuro-Oncology, 2017, 19, vi28-vi28.	0.6	0
174	The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. Journal of Translational Medicine, 2021, 19, 144.	1.8	0
175	Manipulation of Dendritic Cells for Tumor Immunity. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 151-160.	1.1	0
176	Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials. , 2009, , 159-172.		0
177	Abstract 4754: Type-1 dendritic cell vaccines in combination with poly-ICLC-association between positive tetramer response and 6-month progression-free survival in patients with recurrent malignant glioma. , 2010, , .		0
178	Abstract LB-131: Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. , 2012, , .		0
179	Abstract 5375: Modulation of circulating regulatory T-cells and MDSCs in high risk melanoma patients treated with neoadjuvant ipilimumab. , 2012, , .		0
180	Comparison of SearchLight and Luminex multiplex assays: A case study of 27 cytokines in 156 melanoma blood serum samples.. Journal of Clinical Oncology, 2012, 30, 79-79.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Approaches to Immunologic Monitoring of Clinical Trials. , 2013, , 663-694.		0
182	Abstract B44: Enabling in vivo visualization of cellular therapies in the clinic: Maturation of $\hat{\pm}$ DC1 data sets.. , 2013, , .		0
183	Insights into the Process of Translating Emerging Immunologic Paradigms to Clinical Trial in Patients with Cancer. , 2014, , 205-219.		0
184	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation $\hat{\pm}$ positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	0.8	0
185	Abstract 4302: Long term monitoring of circulating regulatory T cells (Treg), myeloid derived suppressor cella (MDSC) and type I effector T cells in melanoma patients treated with neoadjuvant ipilimumab. , 2015, , .		0
186	Regulatory T Cell Response to Factor VIII in Mothers of Children with Hemophilia Inhibitors. Blood, 2015, 126, 3512-3512.	0.6	0
187	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.. Journal of Clinical Oncology, 2016, 34, e21059-e21059.	0.8	0
188	The $\hat{\pm}$ Great Debate $\hat{\pm}$ at Immunotherapy Bridge 2021, December 1st $\hat{\pm}$ 2nd, 2021. Journal of Translational Medicine, 2022, 20, 179.	1.8	0